New and emerging targeted treatments in advanced non-small-cell lung cancer
New and emerging targeted treatments in advanced non-small-cell lung cancer
复制标题
DOI：
10.1016/s0140-6736(16)31473-8
复制
发表时间：
2016-09-03
期刊：
影响因子：
168.9
通讯作者：
Bunn, Paul A., Jr.
中科院分区：
文献类型：
--
作者：
Hirsch, Fred R.;Suda, Kenichi;Bunn, Paul A., Jr.
靶向治疗正在极大地改变肺癌的治疗方法。这些治疗包括针对驱动突变的药物，针对癌细胞增殖和存活中被认为重要的分子的药物，以及抑制免疫检查点分子的药物。随着新靶点的发现、新药物的开发和新联合治疗的使用，这一领域的研究日新月异。研究人员和临床医生也广泛研究了预测性生物标志物和对这些靶向治疗的固有或获得性耐药性的分子机制。我们回顾了晚期非小细胞肺癌患者靶向治疗的最新进展，特别关注已发表的临床试验数据。
Targeted therapies are substantially changing the management of lung cancers. These treatments include drugs that target driver mutations, those that target presumed important molecules in cancer cell proliferation and survival, and those that inhibit immune checkpoint molecules. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers and clinicians have also extensively investigated the predictive biomarkers and the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. We review recent progress in the development of targeted treatments for patients with advanced non-small-cell lung cancer, especially focusing on data from published clinical trials.